Vect-Horus

Vect-Horus develops vectors that facilitate targeting of therapeutic or imaging agents to organs. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers, which limit their access to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder.